MARKET

ALPN

ALPN

Alpine Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.516
+0.106
+3.11%
Closed 16:00 05/27 EDT
OPEN
3.540
PREV CLOSE
3.410
HIGH
3.550
LOW
3.450
VOLUME
11.78K
TURNOVER
--
52 WEEK HIGH
5.35
52 WEEK LOW
2.050
MARKET CAP
65.36M
P/E (TTM)
-1.8667
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALPN stock price target is 11.75 with a high estimate of 17.00 and a low estimate of 8.00.

EPS

ALPN News

More
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
Business Wire · 1d ago
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported Earnings, And Analysts Cut Their Target Price
Simply Wall St. · 05/16 13:11
Alpine Immune Sciences EPS beats by $0.17, beats on revenue
Alpine Immune Sciences (NASDAQ:ALPN): Q1 GAAP EPS of -$0.30 beats by $0.17. Revenue of $1.09M beats by $0.71M. Press Release
seekingalpha · 05/15 01:30
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
Business Wire · 05/14 21:01
84 Biggest Movers From Yesterday
Gainers
Benzinga · 05/13 09:31
UPDATE: Alpine Says NEON-1 Is Now Open For Patient Enrollment
Benzinga · 04/27 13:05
Alpine Immune Sciences Reports Presentation Of Design Of NEON-1 Study Of ALPN-202 At AACR Virtual Meeting
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today presented the design of
Benzinga · 04/27 13:05
Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
Business Wire · 04/27 13:00

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About ALPN

Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
More

Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.